Immune cells engineered to hunt cancer: new trial for hard-to-treat blood cancers
NCT ID NCT06696846
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new cell therapy for people with T-cell lymphoma or acute myeloid leukemia that has come back or not responded to standard treatments. The therapy uses immune cells (NK cells) from donated cord blood that are engineered to recognize and attack cancer cells carrying a protein called CD70. The main goals are to check safety and see if the treatment shrinks tumors or clears leukemia from the bone marrow.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310009, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental CAR-T therapy takes on tough leukemia
- Can lab tests guide better AML treatment choices?
- New transplant combo aims to outsmart relapsed leukemia
- New drug cocktail aims to beat back tough leukemia
- 15-Year safety check for caribou cell therapy patients
- Engineered immune cells take aim at tough blood cancers